Cyclosporine (Atopica) for Canine Atopic Dermatitis: Evidence and Use

Bottom line

• Cyclosporine (ciclosporin; Atopica for Dogs, FDA NADA 141-218) is a calcineurin-inhibitor immunomodulator approved for control of atopic dermatitis (AD) in dogs and is a guideline-endorsed first-line chronic option in the 2015 ICADA guidelines. [1][6]
• Efficacy is well established across multiple RCTs: in the pivotal US/Canada field study (n=265) CADESI scores improved 45% versus a 9% worsening on placebo at 30 days, and in a parallel European RCT ciclosporin matched methylprednisolone (76% vs 63% excellent/good response), with ciclosporin better for lesion control and glucocorticoids faster to act. [1][3]
• Its defining limitation is a slow onset — meaningful pruritus relief takes roughly 4 weeks (up to 4-8 weeks for full effect) — so induction bridging matters: a concurrent short course (~20 days) of prednisolone reduces pruritus within days 3-4 without added immunosuppression signal. [2][5]
• As of July 2026 the safety picture is reassuring: a 15-trial meta-analysis (n=759) found no elevated risk of serious infection, neoplasia, renal failure, or hypertension at label dose; adverse events are predominantly early, self-limiting GI signs. Live vaccines still require a treatment interruption; killed vaccines do not. [7]
• Cyclosporine is a CYP3A4 substrate — azole antifungals (esp. ketoconazole) markedly raise exposure and can be used deliberately to cut dose ~75%; it remains contraindicated in dogs with a history of neoplasia. [1]

Drug facts

• Class: Cyclic-polypeptide calcineurin inhibitor; selective immunomodulator (not an antihistamine, glucocorticoid, JAK inhibitor, or anti-IL-31 biologic).
• Mechanism: Inhibits calcineurin, blocking NFAT nuclear translocation and suppressing T-helper/T-suppressor lymphocyte activation and IL-2 plus downstream Th2 cytokines (IL-4, IL-5, IL-13). Does not directly target the JAK-STAT pathway or IL-31, and does not depress haematopoiesis or phagocytic cell function. [1][10]
• Formulation: A microemulsified/modified formulation is required for adequate oral bioavailability. Approved canine products: Atopica (Elanco) capsules; Cyclavance (Virbac) oral solution, approved 2020 with demonstrated bioequivalence to Atopica capsules. [8]
• Route/dose: Oral; initial induction typically 5 mg/kg once daily for 30 days per label, then taper frequency to every other day or twice weekly toward the minimum effective frequency. Give ≥1 h before or 2 h after a meal — food reduces bioavailability in dogs. [1]
• Onset: Slower than oclacitinib and lokivetmab; significant clinical improvement typically at 4-8 weeks as monotherapy. [8]
• Indication: Control of atopic dermatitis in dogs weighing ≥1.8 kg (FDA NADA 141-218). [1]
• Approval: FDA NADA 141-218 (Elanco US Inc., marketed as Atopica). [1]
• Contraindications: History of neoplasia; hypersensitivity to cyclosporine. [1]
• Label common AEs: Vomiting (30.9%), diarrhoea (20.0%), persistent otitis externa (6.8%), urinary tract infection (3.8%), anorexia (3.0%), lethargy (2.3%), gingival hyperplasia (2.3%); papillomatous skin lesions at higher-than-recommended doses in safety studies. [1]
• Monitoring: Baseline and periodic CBC and serum biochemistry; withhold in active serious infection or known/suspected neoplasia. Therapeutic drug monitoring is NOT indicated for efficacy in dogs (see PK section). [1]

How well does it work? (efficacy evidence)

Pivotal FDA field study (Atopica label basis)

The core efficacy evidence for the FDA label was a multisite, placebo-controlled, double-masked field study at 16 US and Canadian sites enrolling 265 dogs aged 1-10 years. Dogs were randomised to Atopica at the label dose or placebo for 30 days, after which placebo dogs crossed over to Atopica for the remainder of the 4-month study. At the end of the 30-day placebo-controlled period, CADESI scores improved 45% from enrollment in the cyclosporine group while placebo scores worsened 9%. Owner and Veterinary Global Assessment scores improved roughly twice as much as placebo at 4 weeks (p<0.0001 for both), and 74% of cyclosporine-treated dogs showed pruritus improvement over the first 30 days versus 24% of placebo dogs. [1]

Head-to-head vs methylprednisolone (Steffan 2003)

A parallel, blinded, multicentre RCT (CsA n=117, methylprednisolone n=59; 4-month treatment) compared cyclosporine A against methylprednisolone for canine AD. Ciclosporin reduced lesion scores by 52% (95% CI 44-59%) versus 45% (35-56%) for methylprednisolone, and overall efficacy was rated excellent or good in 76% of CsA dogs versus 63% for MP (P<0.05). The trade-off ran along expected mechanistic lines: ciclosporin-treated dogs had more GI adverse events (predominantly vomiting), while MP-treated dogs tended to be more susceptible to infections. This trial, together with the prednisolone-controlled Olivry 2002 study, forms the foundational efficacy base for ciclosporin in canine AD. [3][4]

Onset and comparators (oclacitinib, lokivetmab)

Ciclosporin's onset is materially slower than the newer agents. In the blinded head-to-head RCT versus oclacitinib (Little et al. 2015, n=226 client-owned dogs), pruritus VAS reductions at day 1 were 6.5% for ciclosporin versus 25.6% for oclacitinib, with the gap persisting to day 28 before both converged by day 84 — i.e., comparable medium-term control but a much slower ciclosporin start. [5] Against the anti-IL-31 biologic lokivetmab, the 2017 Moyaert noninferiority trial found lokivetmab superior for pruritus reduction but inferior for skin-lesion (CADESI) scores at Day 28, consistent with ciclosporin's broader T-cell mechanism addressing lesion severity beyond pruritus alone. [8] The practical reading: ciclosporin competes on lesion control and long-term cost rather than speed.

Accelerating onset with concurrent prednisolone (Dip 2013)

The ~4-week lag to maximal pruritus reduction is the main adherence and quality-of-life problem with ciclosporin monotherapy. Dip and colleagues ran a randomised multicentre trial (n=48; 5 US and 5 French dermatology referral centres) comparing ciclosporin at the label dose once daily alone (n=25) against the same regimen plus concurrent prednisolone for the first 20 days (n=23). Owner-assessed pruritus VAS fell significantly as early as days 3-4 in the combination group (p=0.0001, mean reduction 36.3%) versus days 7-8 in the ciclosporin-alone group (p=0.0022, 13.0%). By day 14 the combination group reached an average 72.8% pruritus reduction versus 24.6% for ciclosporin alone; by day 28 the groups converged (65.1% vs 42.4%, not significant). CADESI-03 lesion scores fell significantly from baseline in both groups at days 14 and 28 with no between-group difference. No dogs died or discontinued for adverse events; vomiting was more common with ciclosporin alone (13 events/10 dogs vs 2 events/2 dogs) and mild lethargy more common with concurrent prednisolone (4 cases, resolving 3-8 days after stopping). All AEs were consistent with the established profiles of the individual drugs — no signal of additive immunosuppression at the low, short-term prednisolone doses studied. [2]

Is it safe long term? (adverse events and immunosuppression)

As of July 2026 the long-term safety record is well characterised and broadly reassuring. A systematic review and meta-analysis of 15 clinical trials (n=759 dogs) found adverse events in 55% of ciclosporin-treated dogs in monitored trial settings, but these were predominantly gastrointestinal (vomiting, diarrhoea), early in treatment, and were rare in real-world pharmacovigilance data (~7% in post-marketing surveillance) — reflecting the gap between actively monitored trial populations and routine use. Critically, ciclosporin at the recommended dose was NOT identified as a risk factor for the serious outcomes clinicians most worry about: opportunistic infection, neoplasia, renal failure, or hypertension were not elevated above background at label dose. [7] Pharmacovigilance data corroborate a low population-scale event rate (on the order of ~72 AEs per million capsules sold). [8] Gingival hyperplasia, hirsutism, and cutaneous papillomatosis remain recognised with chronic use. [1]

Contested point — is TDM needed in dogs? The evidence points one way here. Analysis of blood cyclosporine levels in the pivotal canine field study showed no correlation with CADESI or pruritus outcomes, so routine therapeutic drug monitoring is not indicated for efficacy in dogs. [1] This stands in deliberate contrast to cats (below), where PK variability makes TDM essential — the species difference is the point, not a contradiction.

Vaccination planning

Ciclosporin is compatible with killed vaccines (including killed rabies and killed leptospirosis) without treatment interruption. Live attenuated vaccines require a treatment interruption per the licensed recommendation, because ciclosporin may impair the immune response to live vaccine strains and theoretically permit vaccine-strain replication. [7] Practical workflow: confirm vaccination status before starting therapy, schedule any live vaccines within a label-specified interruption window, and use killed products without interruption during ongoing therapy.

Where it fits the treatment ladder (multimodal context)

The 2015 ICADA guidelines place oral ciclosporin alongside oclacitinib among the agents most effective at reducing chronic pruritus and lesion scores, together with oral/topical glucocorticoids and (where available) recombinant interferons. [6] Subsequent approvals — lokivetmab (2016) and newer JAK inhibitors (ilunocitinib, atinvicitinib) — have expanded the toolkit without displacing ciclosporin from chronic management. [8] Its differentiated role is lesion control, once-daily oral administration, a long safety record, and cost: ciclosporin (especially the Cyclavance oral solution) remains more cost-accessible on long-term regimens than monthly injectable lokivetmab or daily JAK inhibitors. [8]

Ciclosporin also sits well within combination and cost-reduction strategies. A 2025 controlled clinical trial (Ferreira et al.) showed an alternating oclacitinib/prednisolone protocol matched oclacitinib-monotherapy CADESI-04 and PVAS outcomes at 73.3% lower cost — a useful illustration of how glucocorticoids and calcineurin inhibitors can be layered against the newer agents to manage spend without sacrificing control. [9] On the pathogenesis side, the ICADA 2023-2024 reviews confirmed skin-barrier dysfunction and cutaneous dysbiosis (notably S. pseudintermedius overgrowth) as core drivers of the flare cycle. [10] Reassuringly, available evidence indicates ciclosporin and prednisone at cAD doses do NOT detectably alter the canine cutaneous microbiota [8] — though this does not lessen the need to identify and treat secondary bacterial/fungal infection, which independently perpetuates inflammation.

Contraindications, precautions & PK

• Contraindications: History of neoplasia; hypersensitivity to cyclosporine. [1]
• Metabolism and interactions: Ciclosporin is extensively metabolised by hepatic (and, to a lesser degree, GI/renal) cytochrome P-450 (CYP3A4) and is a P-glycoprotein substrate/inhibitor. [1] CYP3A4 inhibitors raise exposure: azole antifungals (ketoconazole, itraconazole) can substantially increase plasma concentrations — clinically relevant when treating concurrent fungal infection, and used deliberately with ketoconazole to allow ~75% dose reduction as a validated cost-saving strategy. CYP3A4 inducers (e.g. phenobarbital) may lower levels. Use NSAIDs cautiously (potential additive nephrotoxicity; monitor renal function). No clinically apparent adverse interaction was seen with lokivetmab co-administration in trials, though cytokine-mediated CYP3A4 effects remain theoretically possible. [1][8]
• Feline PK contrast (why monitoring differs by species): Feline ciclosporin PK is markedly more variable and demands TDM, unlike the canine picture above. A 2024 prospective study in cats on high-dose CsA (7 mg/kg q12h) reached steady state by day 5 (~9 doses), with a mean trough of 2,050 ± 964 ng/mL (range 832-3,203) — well above the 200-600 ng/mL immunosuppressive target — and an extreme interindividual coefficient of variation (~47%), so day 5 is the earliest appropriate TDM point on q12h protocols. [11] A 2023 bioavailability study (Atopica for Cats, 7 mg/kg once daily) reported low, highly variable absolute oral bioavailability across cats and supported the 4-hour post-dose concentration (C4h) as a practical AUC surrogate for once-daily feline protocols, with fed/fasted status a key confound to standardise across serial samples. [12] A 6-month feline safety study found serious adverse effects (e.g. prolonged APTT, bone-marrow hypocellularity, lymphoma) only at doses greater than twice the approved label dose, with no significant accumulation beyond the first week at label dosing. [13] Bottom line for cats: TDM is non-negotiable; for dogs it is not indicated for efficacy.

Practical decision support

• When to reach for it: A guideline-endorsed first-line chronic immunomodulator for canine AD — favour it when durable lesion control matters, when once-daily oral dosing suits the owner, or when long-term cost rules out monthly biologics or daily JAK inhibitors. [6][8]
• Set expectations on onset: Counsel owners that full effect takes ~4-8 weeks. For dogs needing faster relief, bridge induction with a short prednisolone course (~20 days max) or oclacitinib — guideline-consistent and, for prednisolone, RCT-supported to cut pruritus within days without an added immunosuppression signal. [2][8]
• Confirm the formulation: Use only a bioequivalent veterinary product (Atopica capsules or Cyclavance oral solution). The liquid format aids owners who struggle with capsules. Human generic ciclosporin formulations carry bioequivalence uncertainty and should be avoided per ICADA caution. [6][8]
• Dose and administer correctly: Induction 5 mg/kg PO q24h for 30 days, then taper frequency (EOD → twice weekly) to the minimum effective frequency; not all dogs reach the lowest frequency. Give on an empty stomach (≥1 h before / 2 h after food). [1]
• Screen interactions before co-prescribing: Check for CYP3A4 inhibitors/inducers and P-gp interactions. Ketoconazole co-dosing is a legitimate, evidence-supported cost-reduction lever in appropriate patients. Monitor renal function if combining with NSAIDs. [1][8]
• Monitoring: Baseline and periodic CBC/serum biochemistry; routine annual wellness monitoring (including chemistry to screen for concurrent renal/hepatic change) remains prudent in long-term patients. Do NOT rely on blood-level TDM for efficacy in dogs (unlike cats). [1]
• Safety counselling: Reassure owners that serious complications are uncommon at label dose; keep vigilant for and treat secondary infections; withhold in known/suspected neoplasia. [1][7]
• Vaccines: Killed vaccines proceed without interruption; live vaccines require a label-specified treatment interruption — verify status before starting and schedule live products accordingly. [7]

Frequently Asked Questions

See the FAQ section rendered from the structured metadata.

Changelog

• 2026-06-07: First published (pivotal FDA field study; Dip 2013 concurrent-prednisolone strategy).
• 2026-07-06: Consolidated hub. Folded in the Steffan 2003 CsA-vs-methylprednisolone RCT and Olivry 2002 foundational evidence; oclacitinib (Little 2015) and lokivetmab (Moyaert 2017) comparators; the Cyclavance 2020 formulation update and ICADA 2023-2024 microbiome/pathogenesis context; the Nuttall 2014 15-trial long-term safety meta-analysis and vaccination planning; the Ferreira 2025 multimodal cost trial; and feline PK/monitoring evidence (Rösch 2024, Kong 2023, Roberts 2014) as a species contrast in the PK section. Reconciled the Atopica canine label to the verified NADA 141-218. Duplicate ICADA 2015 and shared studies deduplicated to single citations.